Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.48 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372410 | 1.00 | KMT2A (0.50) | KMT2AMEN1ALDH1A1KDM1AMAOB | |
| SCHEMBL372409 | 1.00 | KMT2A (0.50) | KMT2AMEN1ALDH1A1KDM1AMAOB | |
| SCHEMBL2143902 | 0.86 | KMT2A (0.56) | KMT2AMEN1ALDH1A1OPRL1YTHDC1 | |
| SCHEMBL2143897 | 0.86 | KMT2A (0.56) | KMT2AMEN1ALDH1A1OPRL1YTHDC1 | |
| SCHEMBL372494 | 0.85 | KMT2A (0.55) | KMT2AMEN1ALDH1A1OPRL1YTHDC1 | |
| SCHEMBL372493 | 0.85 | KMT2A (0.55) | KMT2AMEN1ALDH1A1OPRL1YTHDC1 | |
| SCHEMBL13006996 | 0.85 | KMT2A (0.55) | KMT2AMEN1ALDH1A1OPRL1YTHDC1 | |
| SCHEMBL372733 | 0.84 | MAPT (0.57) | KMT2AMEN1ALDH1A1MAPTGRIN2B | |
| SCHEMBL372734 | 0.84 | MAPT (0.57) | KMT2AMEN1ALDH1A1MAPTGRIN2B | |
| SCHEMBL2143781 | 0.82 | KMT2A (0.50) | KMT2AMEN1ALDH1A1YTHDC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KMT2A 206/4885MEN1 2491/4885ALDH1A1 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.